Squarepoint
BRVE

Squarepoint’s Braveheart Bio BRVE Stock Holding History

Squarepoint’s Portfolio BRVE Stock Details BRVE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$814K Buy
+40,282
New +$1.06M ﹤0.01% 2948

Other funds holding BRVE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Leonard Rickey Investment Advisors
Leonard Rickey Investment Advisors Yakima, Washington $644M AUM 17.66% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Squarepoint's BRVE Position: Q3 2026 in Review

Squarepoint opened a new position in Braveheart Bio (BRVE) in Q3 2026: 40,282 shares worth $814K. The stake represents ﹤0.01% of the portfolio and ranks #2948 among its holdings.

7 funds tracked by Wall St. Rank hold BRVE as of Q3 2026.

  • Squarepoint held 40,282 shares of Braveheart Bio worth $814K as of Q3 2026.
  • Braveheart Bio was a new Squarepoint position in Q3 2026.
  • Braveheart Bio made up ﹤0.01% of Squarepoint's portfolio in Q3 2026, its #2948 holding.
  • 7 funds tracked by Wall St. Rank held Braveheart Bio as of Q3 2026.

Based on Squarepoint's 13F filing for Q3 2026, filed 9 Nov 2026.